PEG-Interferon-α ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study

View/ Open
Issue date
2015Author
Milara, Javier
Outeda Macias, María
Aumente Rubio, Mª Dolores
Más Serrano, Patricio
Aldaz, Azucena
Calvo, Mª Victoria
García Simón, Mª Sergia
Martín Barbero, Marisa
SEFH-PkGen research group
Other authors
Padullés Zamora, Núria
Saavedra Aldrich, Marianne
Tévar Alfonso, Enrique
Saval, Ana
Pastor Clerigues, Alfonso
García, Marta
Margusino Framiñan, Luis
Montero Álvarez, Jose Luis
Merino de Lucas, Esperanza
Herrero, Jose Ignacio
Beunza, Mónica
Conesa Zamora, Pablo
Giménez Manzorro, Álvaro
Comas Sugrañes, Dolors
Cano Marrón, Manuel
Jiménez Mutiloa, Elena
Díaz Ruíz, Pilar
Cortijo, Julio
Suggested citation
Milara, Javier;
Outeda Macias, María;
Aumente Rubio, Mª Dolores;
Más Serrano, Patricio;
Aldaz, Azucena;
Calvo, Mª Victoria;
...
SEFH-PkGen research group.
(2015)
.
PEG-Interferon-α ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study.
Farmacia Hospitalaria, 2015, vol. 39, núm. 1, p. 29-43.
https://dx.doi.org/10.7399/fh.2015.39.1.8547.
Metadata
Show full item recordAbstract
Objective: Dual PEGylated interferon-α (PEG-IFN) and ribavirin therapy has been the main hepatitis C virus (HCV) treatment of the last decade. Current direct-acting antiviral agents have improved the outcome of therapy but also have increased the cost and management complexity of treatment. The current study analyzes host genetics, viral and clinical predictors of sustained viral response (SVR) to dual PEG-IFN and ribavirin therapy in a representative Spanish population.
Methods: Observational prospective multicentre pharmacogenetic cohort study conducted in 12 different hospitals of 12 different Spanish regions. A total of 98 patients with SVR and
106 with non-SVR in response to PEG-IFN and ribavirin therapy were included. 33 single nucleotide polymorphisms located in 24 different genes related with inflammatory, immune and
virus response were selected. Clinical and viral data were also
analyzed as candidate of SVR predictors.
Results: IL-28B (rs12979860, rs7248668, rs8105790, rs8099917) and TNFRSF1B (rs1061622) genotypes, as well as TNFRSF1B/IL-10/TNFα (-308) non-TTG and TNFRSF1B/IL10/IL-4 non-TTC haplotypes together with lower age, lower basal HCV RNA load, higher basal serum LDL cholesterol values, VHC genotypes 2 and 3 and basal low grade fibrosis 0-2 were associated with a SVR in the univariate analysis. Independent predictors of SVR in the multivariate analysis were IL-28B rs12979860 CC, TNFRSF1B/IL-10/IL-4 non-TTC along with low baseline HCV RNA load and HCV genotypes
2 and 3.
Conclusions: IL-28B rs12979860 CC, TNFRSF1B/ IL-10/ IL-4 non-TTC haplotype, low baseline HCV RNA load and HCV genotypes 2 and 3 may help to predict successful outcome to PEG-IFN/ribavirin therapy in Spanish population.
Is part of
Farmacia Hospitalaria, 2015, vol. 39, núm. 1, p. 29-43European research projects
Collections
The following license files are associated with this item: